Upgrade to SI Premium - Free Trial

Mizuho defends Immuneering Corporation (IMRX), 'recommend being opportunistic on IMRX'

June 2, 2026 6:43 AM
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $12.00 price target on Immuneering Corporation (NASDAQ: IMRX).The analyst commented: "With ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments